3.8 Review

Epidemiology, staging and management of mucosal melanoma of the head and neck: a narrative review

期刊

CHINESE CLINICAL ONCOLOGY
卷 12, 期 3, 页码 -

出版社

AME PUBLISHING COMPANY
DOI: 10.21037/cco-23-16

关键词

Mucosal melanoma; head and neck; epidemiology; staging; management

类别

向作者/读者索取更多资源

Mucosal melanoma of the head and neck (MMHN) is a rare and aggressive malignancy with poor prognosis. Current understanding of MMHN's epidemiology, staging, and management has been expanded through recent studies. Tumor resection with clear histological margins remains the mainstay of treatment, while alternative staging models and combination therapies show promise. Ongoing clinical trials and further research are needed to fully understand and optimize management of this aggressive disease.
Background and Objective: Mucosal melanoma of the head and neck (MMHN) are rare, aggressive neoplasms of melanocyte origin that remain incompletely understood and have a poor prognosis, with high rates of locoregional recurrence and distant metastasis. Several recent studies having expanded understanding of MMHN, we undertook a review of the latest evidence pertaining to its epidemiology, staging, and management. Methods: A literature search was conducted for peer-reviewed articles reporting and discussing the epidemiology, staging, and management of MMHN. PubMed, Medline, Embase and the Cochrane Library were searched to identify relevant publications. Key Content and Findings: MMHN remains an uncommon disease. The current TNM staging system for MMHN provides inadequate risk stratification, and consideration of an alternative staging model such as one based on a nomogram may be justifiable. Tumour resection with clear histological margins remains the cornerstone of optimal treatment. Adjuvant radiotherapy may improve locoregional control but does not appear to affect survival. Immune checkpoint inhibitors and c-KIT inhibitors demonstrate promising efficacy in patients with advanced or unresectable mucosal melanomas, and warrant further research exploring the utility of combination therapies. Their roles as adjuvant therapies have not been determined. The efficacy of neoadjuvant systemic therapy is also not yet clear, although early results suggest that it may improve outcomes. Conclusions: New insights into the epidemiology, staging and management of MMHN have transformed the standard of care for this rare malignancy. Nonetheless, the results of ongoing clinical trials and future prospective studies are required to better understand this aggressive disease and optimise its management.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据